Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

#Counterfeit

Grey-market supply, identity testing, vendor accountability stories.

Vendor accountability

BPC-157 Grey Market Risks and Quality

BPC-157 is sold online with no regulatory oversight. What COA testing can and cannot tell you about identity, purity, and contamination.

12 Jun 2026 · PeptideMethods Editorial Team · 6 min read
Vendor accountability

PT-141 Grey Market Risks and Quality

Grey-market PT-141 vials lack the controls of FDA-approved Vyleesi. What COA testing reveals about identity, purity, and contamination.

12 Jun 2026 · PeptideMethods Editorial Team · 6 min read
Vendor accountability

Retatrutide grey market risks

Retatrutide is unapproved and ineligible for compounding. Grey-market vials carry identity, purity, and contamination risks.

12 Jun 2026 · PeptideMethods Editorial Team · 6 min read
Vendor accountability

Semaglutide Grey Market Risks and Quality

Counterfeit Ozempic, compounded semaglutide salt forms, and dosing errors: what regulators have found and what a COA cannot tell you.

12 Jun 2026 · PeptideMethods Editorial Team · 5 min read
Vendor accountability

Semax Grey Market Risks and Quality Testing

Semax is sold online with no regulatory oversight outside Russia. What COA testing reveals about identity, purity, and contamination.

12 Jun 2026 · PeptideMethods Editorial Team · 6 min read
Vendor accountability

Tesamorelin Grey Market Risks and Quality

Tesamorelin is FDA-approved only for HIV lipodystrophy. Grey-market vials sold for off-label use carry identity, purity, and contamination risks.

12 Jun 2026 · PeptideMethods Editorial Team · 6 min read
Vendor accountability

Tirzepatide Grey Market Risks and Quality

Counterfeit Mounjaro pens, compounded tirzepatide after the shortage ended, and FDA recalls: what regulators have found and what a COA cannot tell you.

12 Jun 2026 · PeptideMethods Editorial Team · 5 min read